| Synthetic glycolipid ligands for human iNKT cells as potential therapeutic agents for immunotherapy. | |
| | |
MedLine Citation:
|
PMID: 18855664 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Invariant natural killer T (iNKT) cells are an attractive therapeutic target in autoimmune diseases, since they play a major role in immune regulation. iNKT cells recognize glycolipid antigens presented by CD1d molecules that resemble the non-polymorphic MHC class I protein. alpha-galactosylceramide (alpha-GalCer) isolated from marine sponge has long been used as a prototype iNKT cell ligand in the laboratory. As alpha-GalCer is the most efficacious ligand for iNKT cells, its potential to treat autoimmune disease has been evaluated in animal models. Previous studies showed that alpha-GalCer effectively suppressed disease in some autoimmunity models, but not in others. This inconsistency may be attributed to the ability of alpha-GalCer to induce the production of both proinflammatory Th1 and anti-inflammatory Th2 cytokines by iNKT cells. To overcome this issue, we and other groups have synthesized new, unnatural glycolipids by modifying the structure of alpha-GalCer. These efforts have led to an identification of glycolipid compounds that provoke the production of Th2 (but not Th1) cytokines by iNKT cells. Among these novel ligands, an alpha-GalCer analogue named OCH, which contains a truncated sphingosine chain, induces a Th2 biased response by murine iNKT cells. Here we describe that OCH also polarizes human iNKT cells towards Th2, which opens up a new avenue for the clinical application of glycolipid compounds in treating of autoimmune diseases such as multiple sclerosis. The pursuit of synthetic glycolipid antigens has the great potential to lead to a better understanding of the regulatory effects of human iNKT cells and development of a new therapeutic agent for autoimmune diseases. |
| | |
Authors:
|
Manabu Araki; Sachiko Miyake; Takashi Yamamura |
Related Documents
:
|
15270864 - The number of cd8+ t cells and nkt cells increases in the aqueous humor of patients wit... 3130194 - Abnormal t cells from mrl/mp-lpr/lpr mice do not respond to anti-t-cell-receptor antibo... 10648124 - Interleukin-10 reduces natural killer (nk) sensitivity of tumor cells by downregulating... 2966204 - T-b collaboration in the in vitro anti-sm autoantibody response of mrl/mp-lpr/lpr mice. 18025164 - Intravenous transfusion of bcr-activated b cells protects nod mice from type 1 diabetes... 9144324 - Modulation of glutathione level during butyrate-induced differentiation in human colon ... |
Publication Detail:
|
Type: Journal Article; Review |
Journal Detail:
|
Title: Current medicinal chemistry Volume: 15 ISSN: 0929-8673 ISO Abbreviation: Curr. Med. Chem. Publication Date: 2008 |
Date Detail:
|
Created Date: 2008-10-15 Completed Date: 2008-10-31 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 9440157 Medline TA: Curr Med Chem Country: Netherlands |
Other Details:
|
Languages: eng Pagination: 2337-45 Citation Subset: IM |
Affiliation:
|
Department of Immunology, National Institute of Neuroscience, National Center of Neurology and Psychiatry, Kodaira, Tokyo 187-8502, Japan. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Animals Cytokines / immunology Disease Glycolipids / chemical synthesis*, chemistry, immunology* Humans Immunotherapy* Ligands T-Lymphocytes, Cytotoxic / immunology* |
| Chemical | |
Reg. No./Substance:
|
0/Cytokines; 0/Glycolipids; 0/Ligands |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Cells under pressure - treatment of eukaryotic cells with high hydrostatic pressure, from physiologi...
Next Document: Cytochrome P450-activated prodrugs: targeted drug delivery.